NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
3.730
+0.170 (4.78%)
At close: Jun 26, 2026, 4:00 PM EDT
3.810
+0.080 (2.14%)
After-hours: Jun 26, 2026, 7:59 PM EDT
NRx Pharmaceuticals Revenue
NRx Pharmaceuticals had revenue of $1.07M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $2.29M. In the year 2025, NRx Pharmaceuticals had annual revenue of $1.23M.
Revenue (ttm)
$2.29M
Revenue Growth
n/a
P/S Ratio
58.88
Revenue / Employee
$79,069
Employees
29
Market Cap
135.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.23M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 123.87M |
| ADC Therapeutics | 79.18M |
| Spero Therapeutics | 61.19M |
| Alpha Cognition | 10.83M |
| Coya Therapeutics | 7.94M |
| Molecular Partners AG | 856.30K |
| Connect Biopharma Holdings | 233.00K |
| Genelux | 8.00K |
NRXP News
- 1 day ago - NRx Pharmaceuticals issues response to Kadima statements - TheFly
- 1 day ago - NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute - GlobeNewsWire
- 1 day ago - NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System - GlobeNewsWire
- 2 days ago - Kadima Neuropsychiatry Institute alleges NRx breached contract - TheFly
- 2 days ago - Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition - Business Wire
- 3 days ago - ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics - PRNewsWire
- 4 days ago - NRx Pharmaceuticals announces FDA grant of expanded access protocol for NRX-101 - TheFly
- 4 days ago - NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression - GlobeNewsWire